Eylea

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
0102020122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
INTRODUCTION Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several… (More)
Is this relevant?
2017
2017
PURPOSE We report the 3-month efficacy of monthly intravitreal ziv-aflibercept in patients with diabetic macular oedema (DME… (More)
Is this relevant?
2016
2016
PURPOSE We determined the intraocular pharmacokinetic properties of intravitreally injected aflibercept (Eylea) in a rabbit model… (More)
Is this relevant?
2016
2016
An 84-year-old man had air entry into the anterior chamber following intravitreal injection. The air bubble was reabsorbed over… (More)
Is this relevant?
2015
2015
In their retrospective study, Lotery and Regnier1 comprehensively assessed the real world usage of intravitreal ranibizumab… (More)
Is this relevant?
2015
2015
The arrival of aflibercept adds a new player to the treatment strategy for exudative macular diseases. The VIEW study proved that… (More)
Is this relevant?
2014
2014
 
Is this relevant?
2014
2014
Retinal angiomatous proliferation (RAP) is a type of neovascular age-related macular degeneration (AMD) with a reportedly poor… (More)
  • figure 1
  • figure 2
Is this relevant?
2013
2013
A flibercept (Eylea) is the most recent anti– vascular endothelial growth factor (antiVEGF) product approved by the US Food and… (More)
  • figure 1
  • figure 2
  • figure 1
Is this relevant?
2013
2013
Antivascular endothelial growth factor (VEGF) agents have revolutionised our treatment paradigms and therapeutic approach to… (More)
  • table 1
Is this relevant?